Cilcare
Created in 2014
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
265 5,067Activities
Technologies
Entity types
Location
Rue du Professeur Joseph Anglada, 34090 Montpellier, France
Montpellier
France
Employees
Scale: 11-50
Estimated: 46
SIREN
803146125Engaged corporates
43
13 39Added in Motherbase
5 years, 8 months ago
biotech Value proposition
MAKING HEARING A PRIORITY
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.
CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.
CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.
We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
hearing disorders, tinnitus, hearing loss, pharmaceutical development, pharmacology, clinical development, preclinical development, GLP ototoxicology, hearing loss, tinnitus, auditory safety, ear disorders, AI, and precision medicineOriginal language
MAKING HEARING A PRIORITY
CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.
CILCARE External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.
CILCARE Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.
CILCARE Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.
We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.
Accueil - Cilcare
https://www.cilcare.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 AQUA-VALLEY Public business cluster, Non-profit Organizations | AQUA-VALLEY Public business cluster, Non-profit Organizations | Other 19 Apr 2024 | | |
 Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Boehringer Ingelheim Pharmaceutical, Pharmaceutical Manufacturing, Animal Health | Other 20 Mar 2024 | | |
 Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Other 20 Mar 2024 | | |
 Banque Populaire Banking | Banque Populaire Banking | Other 24 Jun 2016 29 Feb 2024 | | |
 EY Consulting, audit, IT Services and IT Consulting | EY Consulting, audit, IT Services and IT Consulting | Other 29 Feb 2024 | | |
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Other 29 Feb 2024 | | |
 | SATT AxLR | Other 22 Nov 2024 | | |
 | Réseau SATT | Other 5 Jun 2023 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Other 20 Nov 2023 | | |
 Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Other 27 Nov 2023 | | |